Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Page 2 of 6
Jul 21, 2026Despite the growing prominence of artificial intelligence in clinical medicine, existing payment models are proving inefficient and potentially costly. The Peterson Health Technology Institute’s recent study explores why current structures may stifle innovation or accelerate spending, laying out core recommendations for a more sustainable financing approach.
Jul 20, 2026BMS becomes the third major drugmaker in less than a year to announce the construction of the 'largest' NVIDIA AI supercomputer in pharma, reflecting escalating competition and unprecedented digital infrastructure investment across the industry.
Jul 9, 2026Biopharma’s embrace of artificial intelligence has been enthusiastic, but a new analysis counsels that next-generation AI-enabled drug discovery will remain limited unless companies redesign how their R&D units are organized and operate. This post explores the implications and requirements for transformative change in the industry.
Jul 8, 2026Artificial intelligence has demonstrated remarkable potential in healthcare, especially in environments where conditions are carefully controlled. However, the true test emerges not in laboratory settings, but in real-world clinical workflows—where integration brings up sometimes-troublesome questions about who bears responsibility, who has authority, and how accountability is maintained. As healthcare leaders and clinicians embrace AI, the dynamics of this relationship become a microcosm of wider tensions in health innovation—and demand careful analysis if integration is to benefit both practitioners and patients.
Jul 8, 2026The little-known AI biotech Xaira Therapeutics has long operated behind the curtain, backed by over a billion dollars in initial funding. Now, signs indicate that Xaira is shifting its strategy from secrecy to collaboration in a bid to validate an emerging drug pipeline—marking an intriguing inflection point both for the company and the wider industry. With enormous resources and an enigmatic approach, Xaira’s search for external partners raises broader questions about transparency, trust, and validation within the rapidly evolving field of AI-driven pharmaceutical innovation.
Jul 5, 2026While AI promises to revolutionize many aspects of healthcare, mental health professionals argue that certain skills—such as navigating patient discomfort, challenging assumptions, and asking deeper questions—remain uniquely human. Bridging the gap between technology and compassionate care is increasingly seen as essential in the evolving mental health landscape.
Jul 4, 2026As static chatbots reach their limits, the emergence of agentic AI promises to fundamentally change how healthcare tasks are managed for patients and providers alike. This article examines the real-world opportunities and dilemmas that come with entrusting sensitive healthcare functions to autonomous AI agents.
Jul 1, 2026AI giant Anthropic, after achieving household-name status in technology, is making bold advances into drug development. This move signals a possible industry-wide transformation as tech behemoths join the AI drug discovery race.
Jun 30, 2026With an explosion of interest in artificial intelligence applications for drug discovery and biomedical research, the official release of Claude Science by Anthropic marks a significant development for the life sciences industry. This new application, tailored for the unique needs of researchers and pharmaceutical professionals, optimizes emerging AI technology to fundamentally reshape how complex scientific problems are tackled.
Jun 29, 2026Edison Scientific, a leader in AI-driven science, and investment firm Population Health Partners are joining forces to develop new biotechs empowered by artificial intelligence. The partnership will harness the potential of AI agents for drug discovery and development, promising to reinvent how biotech startups are founded and scaled in a rapidly evolving scientific landscape.
Jun 27, 2026AI adoption in medicine has accelerated, but clinicians and researchers warn that generative models fall short in explaining their outputs. Transparent, causally rooted systems could bridge the trust gap and improve care, marking a pivotal inflection point for AI in clinical settings.
Jun 26, 2026AI’s technological prowess in healthcare is evident, but many projects stall once initial pilots end. This deep-dive analysis explores why capability alone is not enough, identifying systemic obstacles and offering context on moving from pilot to practice.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.